BACKGROUND: Vaccines against Streptococcus pneumoniae, Neisseria meningitidis, and Hemophilus influenzae type b induce functional opsonic or bactericidal antibodies to surface capsular polysaccharides (CP). Targeting the comparable Staphylococcus aureus CP seems logical, but to date such efforts have failed in human trials. Studies using immunization-induced animal antibodies have documented interference in opsonic and protective activities of antibodies to CP by antibodies to another S. aureus cell surface polysaccharide, poly-N-acetyl glucosamine (PNAG). Here we evaluated whether natural antibody to PNAG in normal human serum (NHS) had a similar deleterious effect. METHODS: Functional and/or protective activities of antibody to S. aureus CP and PNAG antigens in patients with bacteremia, in mice immunized with combinations of CP and PNAG conjugate vaccines, and in serum samples of healthy subjects with natural antibody to PNAG, to which immunization-induced animal antibodies to CP antigens were added, were evaluated. RESULTS: Antibodies to PNAG and CP that mutually interfered with opsonic killing of S. aureus were detected in 9 of 15 bacteremic patients. Active immunization of mice with combinations of PNAG and CP conjugate antigens always induced antibodies that interfered with each other's functional activity. Non-opsonic natural antibodies to PNAG found in NHS interfered with the functional and protective activities of immunization-induced antibody to CP antigens during experimental infection with S. aureus. CONCLUSIONS: Both immunization-induced animal antibodies and natural antibodies to PNAG in NHS interfere with the protective activities of immunization-induced antibody to S. aureus CP5 and CP8 antigens, representing potential barriers to successful use of CP-specific vaccines.
BACKGROUND: Vaccines against Streptococcus pneumoniae, Neisseria meningitidis, and Hemophilus influenzae type b induce functional opsonic or bactericidal antibodies to surface capsular polysaccharides (CP). Targeting the comparable Staphylococcus aureus CP seems logical, but to date such efforts have failed in human trials. Studies using immunization-induced animal antibodies have documented interference in opsonic and protective activities of antibodies to CP by antibodies to another S. aureus cell surface polysaccharide, poly-N-acetyl glucosamine (PNAG). Here we evaluated whether natural antibody to PNAG in normal human serum (NHS) had a similar deleterious effect. METHODS: Functional and/or protective activities of antibody to S. aureus CP and PNAG antigens in patients with bacteremia, in mice immunized with combinations of CP and PNAG conjugate vaccines, and in serum samples of healthy subjects with natural antibody to PNAG, to which immunization-induced animal antibodies to CP antigens were added, were evaluated. RESULTS: Antibodies to PNAG and CP that mutually interfered with opsonic killing of S. aureus were detected in 9 of 15 bacteremic patients. Active immunization of mice with combinations of PNAG and CP conjugate antigens always induced antibodies that interfered with each other's functional activity. Non-opsonic natural antibodies to PNAG found in NHS interfered with the functional and protective activities of immunization-induced antibody to CP antigens during experimental infection with S. aureus. CONCLUSIONS: Both immunization-induced animal antibodies and natural antibodies to PNAG in NHS interfere with the protective activities of immunization-induced antibody to S. aureus CP5 and CP8 antigens, representing potential barriers to successful use of CP-specific vaccines.
Authors: Henry Shinefield; Steven Black; Ali Fattom; Gary Horwith; Scott Rasgon; Juan Ordonez; Hock Yeoh; David Law; John B Robbins; Rachel Schneerson; Larry Muenz; Steve Fuller; Joanie Johnson; Bruce Fireman; Harry Alcorn; Robert Naso Journal: N Engl J Med Date: 2002-02-14 Impact factor: 91.245
Authors: F Y Lin; V A Ho; H B Khiem; D D Trach; P V Bay; T C Thanh; Z Kossaczka; D A Bryla; J Shiloach; J B Robbins; R Schneerson; S C Szu Journal: N Engl J Med Date: 2001-04-26 Impact factor: 176.079
Authors: A Fattom; R Schneerson; D C Watson; W W Karakawa; D Fitzgerald; I Pastan; X Li; J Shiloach; D A Bryla; J B Robbins Journal: Infect Immun Date: 1993-03 Impact factor: 3.609
Authors: Melissa J Karau; Mulualem E Tilahun; Ashton Krogman; Barbara A Osborne; Richard A Goldsby; Chella S David; Jayawant N Mandrekar; Robin Patel; Govindarajan Rajagopalan Journal: Virulence Date: 2016-12-07 Impact factor: 5.882
Authors: Daniel R Lu; Yann-Chong Tan; Sarah Kongpachith; Xiaoyong Cai; Emily A Stein; Tamsin M Lindstrom; Jeremy Sokolove; William H Robinson Journal: Clin Immunol Date: 2014-03-01 Impact factor: 3.969
Authors: Taylor C Stevenson; Colette Cywes-Bentley; Tyler D Moeller; Kevin B Weyant; David Putnam; Yung-Fu Chang; Bradley D Jones; Gerald B Pier; Matthew P DeLisa Journal: Proc Natl Acad Sci U S A Date: 2018-03-19 Impact factor: 11.205